In recent trading, shares of Intra-Cellular Therapies Inc (Symbol: ITCI) have crossed above the average analyst 12-month target price of $65.14, changing hands for $65.64/share. When a stock reaches ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was ...

We recently published a list of 10 Firms Dominate Monday Upsurge. In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against other firms that ...

Intra-Cellular Therapies' flagship drug, CAPLYTA, saw a 63% increase in the number of psychiatrists prescribing it in 2023. The company is seeking FDA approval to expand CAPLYTA's use to treat Major ...

Intra-Cellular Therapies Inc. ITCI is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is ...

Mixed features are defined as “a patient having co-occurring subthreshold manic symptoms during their depressive episode or a patient having co-occurring subthreshold depressive symptoms during their ...

Intra-Cellular Therapies Inc. Annual cash flow by MarketWatch. View ITCI net cash flow, operating cash flow, operating expenses and cash dividends.